| Drug Name |
Dulaglutide |
| Drug ID |
BADD_D00733 |
| Description |
Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM).[A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events. It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations.[L34665] |
| Indications and Usage |
Dulaglutide is as an adjunct therapy to diet and exercise for glycemic control in adults with type 2 diabetes mellitus. Additionally, it is indicated to reduce the risk of major adverse cardiovascular events (MACE) in adult type 2 diabetes mellitus patients with cardiovascular disease or multiple cardiovascular risk factors.[L30380] |
| Marketing Status |
approved; investigational |
| ATC Code |
A10BJ05 |
| DrugBank ID |
DB09045
|
| KEGG ID |
D09889
|
| MeSH ID |
C555680
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D03NAW
|
| NDC Product Code |
54568-003; 63419-0525; 62195-433; 0002-3182; 50090-3484; 0002-1434; 62195-434; 50090-3483; 50090-6456; 62381-1433; 0002-1402; 50090-5467; 0002-1433; 50090-6453; 62381-1434; 0002-1401; 0002-2236; 54568-001 |
| UNII |
WTT295HSY5
|
| Synonyms |
dulaglutide | LY 2189265 | LY-2189265 | LY2189265 | Trulicity |
